The Prevalence of Malnutrition and Sarcopenia in Swiss Rehabilitation Settings

Browse trials for

• Malnutrition 1,619
• Sarcopenia 1,240

Keywords

• malnutrition
• sarcopenia
• rehabilitation
• prevalence
• Nutritional Risk Screening
• handgrip strength

Malnutrition

1,619 studies on the registry are indexed under Malnutrition; 241 are open to participants now.

This study's enrollment of 550 is above the median of 206 across 401 observational studies indexed under Malnutrition.

Lead sponsor

This is the only study on the registry with Undine Lehmann, Dr. as lead sponsor.

Study population

Primary outcomes

1. Prevalence of malnutrition - Risk for malnutrition

   The risk for malnutrition will be screened by the Nutritional Risk Screening (NRS-2002, in points). NRS has a scale from 0 to 7 points; higher points indicate a higher risk for malnutrition.

   Time frame: Within 7 days after admission

2. Body weight

   (in kg)

   Time frame: Within 7 days after admission

3. Height

   (in cm)

   Time frame: Within 7 days after admission

4. Body Mass Index

   (calculated by weight and height in kg/m2)

   Time frame: Within 7 days after admission

5. Weight loss

   Weight loss (in percent in six categories - \<5 percent within the last 6 months, 5-10 percent within the last 6 months, \>10 percent within the last 6 months; \<10 percent in more than 6 months, 10 -20 percent in more than 6 months, \>20 percent in more than 6 months)

   Time frame: Within 7 days after admission

6. Reduced energy intake

   Reduced energy intake (in percent of intake versus requirement in three categories: less than 50 percent of energy requirement covered for more than 1 week, any reduced energy intake versus requirement for \>2 weeks, no reduced energy intake)

   Time frame: Within 7 days after admission

7. Muscle mass by Bioelectrical Impedance Analysis (BIA) - Part 1

   Resistance (in Ohm) and Reactance (in Ohm)

   Time frame: Within 7 days after admission

8. Muscle mass by Bioelectrical Impedance Analysis (BIA) - Part 2

   Resistance (in Ohm) and Reactance (in Ohm) measured with BIA are combined with further information on weight, height, sex and age to calculate the appendicular skeletal muscle mass index (in kg/m2)

   Time frame: Within 7 days after admission

9. Prevalence of malnutrition - Confirmed diagnosis and severity of malnutrition

   In case of positive screening, diagnosis of malnutrition will be confirmed and severity assessed according to the Global Leadership Initiative on Malnutrition (GLIM) criteria using the following measures described above: weight (in kg); height (in cm); Body Mass Index (calculated by weight and height in kg/m2); weight loss (in percent in six categories - \<5 percent within the last 6 months, 5-10 percent within the last 6 months, \>10 percent within the last 6 months; \<10 percent in more than 6 months, 10 -20 percent in more than 6 months, \>20 percent in more than 6 months); reduced energy intake (in percent of intake versus requirement in three categories: less than 50 percent of energy requirement covered for more than 1 week, any reduced energy intake versus requirement for \>2 weeks, no reduced energy intake); Bioelectrical impedance analysis for muscle mass: resistance (in Ohm), reactance (in Ohm), Appendicular skeletal muscle mass index (in kg/m2)

   Time frame: Within 7 days after admission

10. Prevalence of malnutrition - overall

    Overall prevalence of malnutrition will be reported in percent

    Time frame: Calculated through study completion after five months recruitment duration

Secondary outcomes

1. Prevalence of sarcopenia - Risk for sarcopenia by SARC-F

   according to European Working Group on Sarcopenia in Older People (EWGSOP2) criteria. Screening will be performed by the Strength, assistance with walking, rising from a chair, climbing stairs, and falls (SARC-F) questionnaire (in points). SARC-F has a scale from 0 - 10 with higher score indicating higher risk for sarcopenia.

   Time frame: Within 7 days after admission

2. Prevalence of sarcopenia - Risk for sarcopenia by handgrip strength

   according to European Working Group on Sarcopenia in Older People (EWGSOP2) criteria. Screening will be performed by handgrip strength (in kPa)

   Time frame: Within 7 days after admission

3. Prevalence of sarcopenia - Risk for sarcopenia

   according to European Working Group on Sarcopenia in Older People (EWGSOP2) criteria. Screening will be performed by Chair Stand Test (in seconds)

   Time frame: Within 7 days after admission

4. Prevalence of sarcopenia - Diagnosis of sarcopenia

   In case of positive screening, muscle mass will be measured by BIA via resistance (in Ohm), reactance (in Ohm). Resistance (in Ohm) and Reactance (in Ohm) measured by BIA is combined with further information on weight, height, sex and age to calculate the appendicular skeletal muscle mass index in kg/m2. Diagnosis is confirmed if the appendicular skeletal muscle mass index is below a threshold (\<7.0 kg/m2 for male and \< 5.5. kg/m2 for female).

   Time frame: Within 7 days after admission

5. Prevalence of sarcopenia - Severity of sarcopenia

   In case of positive screening, severity of sarcopenia will be analysed by Timed Up and Go Test (in seconds).

   Time frame: Within 7 days after admission

6. Prevalence of sarcopenia - Overall

   Overall prevalence of sarcopenia will be reported in percent

   Time frame: Calculated through study completion after five months recruitment duration

7. Changes of handgrip strength between admission and discharge of rehabilitation

   Handgrip strength (in kPa)

   Time frame: At admission and 21 days after admission (or, if admission occurs before 21 days and the length of stay was at least 14 days than within 3 days before discharge)

8. Changes of body weight between admission and discharge of rehabilitation

   body weight (in kg)

   Time frame: At admission and 21 days after admission (or, if admission occurs before 21 days and the length of stay was at least 14 days than within 3 days before discharge)

9. Changes of BMI between admission and discharge of rehabilitation

   BMI (calculated in kg/m2)

   Time frame: At admission and 21 days after admission (or, if admission occurs before 21 days and the length of stay was at least 14 days than within 3 days before discharge)

10. Changes of Functional Independence Measure between admission and discharge of rehabilitation

    Functional Independence Measure (FIM) (in points). FIM has a scale from 18 to 126 points. Higher points indicate a higher independence for activities of daily living.

    Time frame: At admission and 21 days after admission (or, if admission occurs before 21 days and the length of stay was at least 14 days than within 3 days before discharge)

Publications

• Cederholm T, Jensen GL, Correia MITD, Gonzalez MC, Fukushima R, Higashiguchi T, Baptista G, Barazzoni R, Blaauw R, Coats A, Crivelli A, Evans DC, Gramlich L, Fuchs-Tarlovsky V, Keller H, Llido L, Malone A, Mogensen KM, Morley JE, Muscaritoli M, Nyulasi I, Pirlich M, Pisprasert V, de van der Schueren MAE, Siltharm S, Singer P, Tappenden K, Velasco N, Waitzberg D, Yamwong P, Yu J, Van Gossum A, Compher C; GLIM Core Leadership Committee; GLIM Working Group. GLIM criteria for the diagnosis of malnutrition - A consensus report from the global clinical nutrition community. Clin Nutr. 2019 Feb;38(1):1-9. doi: 10.1016/j.clnu.2018.08.002. Epub 2018 Sep 3. PubMed 30181091 ↗
• Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T, Cooper C, Landi F, Rolland Y, Sayer AA, Schneider SM, Sieber CC, Topinkova E, Vandewoude M, Visser M, Zamboni M; Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019 Jan 1;48(1):16-31. doi: 10.1093/ageing/afy169. PubMed 30312372 ↗
• Kondrup J, Rasmussen HH, Hamberg O, Stanga Z; Ad Hoc ESPEN Working Group. Nutritional risk screening (NRS 2002): a new method based on an analysis of controlled clinical trials. Clin Nutr. 2003 Jun;22(3):321-36. doi: 10.1016/s0261-5614(02)00214-5. PubMed 12765673 ↗

Individual participant data

Plan to share: Undecided